



VALIDATING ALTERNATIVE MEDICINE THROUGH CLINICAL RESEARCH - A BRIDGING TRADITION PRACTICE

Niranjan Sanjay Chaudhari^{1*}, Mohammad Safwan Akbar Ali Khan¹, Mohammed Fahim Abdul Azim Khan¹,
Shaikh Mohd. Owais Mohd. Azam¹, Bhavesh Shirishchandra Sonar¹, Kishankumar Hiteshbhai Patel¹ and
S. P. Srinivas Nayak²

¹Pharm D Intern, Department of Pharmacy Practice, Parul Institute of Pharmacy & Research, Parul University, Vadodara, Gujarat.

²Assistant Professor, Department of Pharmacy Practice, Parul Institute of Pharmacy & Research, Parul University, Vadodara, Gujarat.



*Corresponding Author: Niranjan Sanjay Chaudhari

Pharm D Intern, Department of Pharmacy Practice, Parul Institute of Pharmacy & Research, Parul University, Vadodara, Gujarat.

Article Received on 26/11/2024

Article Revised on 17/12/2024

Article Accepted on 07/01/2025

ABSTRACT

Alternative Medicine (AM) encompasses a broad spectrum of holistic practices rooted in traditional knowledge, widely embraced globally to address various health concerns. Approximately two-thirds of the global population utilizes AM, with significant prevalence in countries like the USA, Canada, and Australia. The COVID-19 pandemic further heightened interest in AM due to the absence of definitive treatments and a growing demand for personalized and non-invasive therapeutic options. Key factors driving its popularity include escalating costs of conventional healthcare, limited interaction time with providers, and concerns over pharmaceutical adverse effects and antimicrobial resistance. Prominent AM practices include Ayurveda, Traditional Chinese Medicine (TCM), Unani, herbal remedies, homeopathy, and acupuncture. Despite its cultural and therapeutic significance, concerns over the safety and efficacy of AM persist, necessitating rigorous scientific validation to ensure integration into evidence-based medical frameworks.

KEYWORDS: Alternative medicine, Clinical research, Validation.

INTRODUCTION

Alternative medicine encompasses a diverse range of holistic practices rooted in traditional knowledge, widely employed to address various health challenges. Globally, approximately two-thirds of the population utilizes AM, often as a preferred alternative to conventional healthcare. Its prevalence is notable in countries such as the USA (42%), Australia (48%), Canada (70%), and France (49%), underscoring its cultural and practical significance.^[1-4] The COVID-19 pandemic further accelerated interest in AM, driven by the absence of definitive treatments and a growing demand for alternative therapeutic options. Factors contributing to its popularity include the rising costs of conventional healthcare, limited interaction time with providers, concerns over antimicrobial resistance, adverse effects of pharmaceuticals, and the increasing need for personalized approaches to chronic and emerging diseases.^[5-6]

Key AM practices include traditional systems like Ayurveda, Traditional Chinese Medicine (TCM), and

Unani, along with herbal remedies, homeopathy, acupuncture, naturopathy, and chiropractic care. These modalities appeal to individuals seeking less invasive and culturally congruent alternatives to pharmacological or surgical interventions.^[7-8] However, debates surrounding their safety and efficacy persist, highlighting the need for evidence-based integration into modern medical practices. Combining validated AM therapies with conventional medicine can offer a balanced, patient-centered approach, enhancing overall healthcare outcomes. The growing global interest in AM reflects a shift toward holistic healthcare.^[8] Despite its long history and potential therapeutic benefits, many AM modalities lack rigorous scientific validation, limiting their acceptance within evidence-based frameworks. Bridging this gap necessitates robust clinical research to evaluate the safety, efficacy, and mechanisms of action of AM therapies. Methodologies such as preclinical studies, randomized controlled trials (RCTs), observational research, and meta-analyses are essential for establishing credibility, achieving regulatory approval, and fostering trust among healthcare professionals and patients.^[9-11]

Although challenges such as methodological variability and standardization persist, advancements in research designs, bioinformatics, and interdisciplinary collaboration offer opportunities to align traditional practices with scientific rigor. Integrating AM into mainstream healthcare, supported by validated clinical evidence, can create a complementary model that leverages the strengths of both traditional and modern medicine. This review underscores the importance of clinical research as a validation pathway for AM, advocating for a collaborative, evidence-based approach to enhance healthcare delivery.

VALIDATION PATHWAY FOR ALTERNATIVE MEDICINE

Validation pathway for alternative medicine, specifically focusing on Traditional Interventions (TIs) in Ayush Systems of Medicine (ASM).

1. Identification and Verification Accurate Identification^[12,19,21]: The first step involves the precise identification of the medicinal plant or formulation. This is crucial for ensuring the correct use of the plant or formulation in clinical studies.

Methods include: Botanical Taxonomy: Classification and naming of plants. Macroscopic and Microscopic Examination: Visual and microscopic analysis to identify plant parts. Chemical Methods: Use of chemical tests to identify active compounds. DNA Barcoding: Genetic identification to ensure the correct species is used. Verification of Therapeutic Indications: The therapeutic uses of the plant or formulation are verified from authoritative literature and recognized pharmacopoeias, such as those listed in the Drug and Cosmetic Act, 1940.

2. Preclinical Studies In Vivo and In Vitro Studies^[23,26]: These studies are conducted to explore the mechanism of action, toxicity, efficacy, and dosage range of the interventions. Although TIs often skip this step due to their historical use, it is essential in conventional drug development. Safety Studies: Preclinical safety studies assess potential adverse effects, organ-targeted toxicity, immunotoxicity, embryo/fetal and prenatal toxicity, mutagenicity/genotoxicity, and carcinogenicity.

3. Clinical Trials Design and Conduct^[22,24]: Clinical trials are designed to validate the safety and efficacy of TIs. These trials should follow ethical and regulatory guidelines, such as: Good Clinical Practices (GCP): Ethical and scientific quality standards for designing, conducting, and reporting trials. CONSORT 2010 Statement: Guidelines for reporting randomized controlled trials. Phases of Clinical Trials: Phase I: Initial safety trials in a small group of healthy volunteers. Phase II: Trials to assess efficacy and side effects in a larger group. Phase III: Large-scale trials to confirm efficacy, monitor side effects, and compare with standard treatments. Reverse Pharmacology: This approach involves selecting an effective drug based on

retrospective treatment outcomes, followed by clinical trials to confirm safety and efficacy. The active ingredient is then identified for drug standardization and quality control. This method can reduce time and cost compared to conventional drug development.

4. Regulatory Approval Current Scenario

^[17,18,22,24]

There is no formal mechanism in India for the approval and registration of validated TIs. The proposed Minimum Standards (MS) for validation would include criteria for safety, therapeutic efficacy, quality control, and pharmacovigilance. Proposed Minimum Standards (MS): These standards would guide the clinical research process and ensure the generation of quality evidence. They may include: Hypothesis Testing: Clear definition of the trial hypothesis (superiority, equivalence, or inferiority). Trial Design: Selection of appropriate trial design (randomized controlled trials, single-arm studies, etc.). Sample Size Estimation: Justification for sample size based on power, type I error, and effect size. Randomization and Allocation Concealment: Methods to ensure unbiased allocation of participants. Data Analysis: Preference for Intention-to-Treat analysis over per-protocol analysis.

5. Publication and Dissemination Publication Criteria

^[15,16,20,27]

The outcomes of clinical trials are published in peer-reviewed journals, following specific guidelines for manuscript preparation and ethical clearance. This step is crucial for the acceptance and integration of TIs into mainstream healthcare. Ethical Clearance: Obtaining clearance from Institutional Ethics Committees or Institutional Review Boards is mandatory before enrolling participants in the trial. Trial Registration: Registration of the trial in national or international registries before participant enrolment is required.

6. Third-Party Endorsement Independent Approval

^[24,25,28]

For the scientific validation of TIs, it is recommended that an independent third party or agency approve the clinical validation studies based on the proposed MS. This endorsement would enhance the credibility and acceptability of TIs.

CHALLENGES FOR VALIDATION

^[12-14,16]

- **Drug Identification and Standardization:** Accurate identification and standardization of plant-based materials are crucial to ensure the consistency, quality, and authenticity of herbal products used in medicine. This involves employing advanced techniques such as DNA barcoding, chromatography, and spectroscopic methods to verify the identity of plant species and their active constituents. Such measures enhance the reliability of traditional medicines and ensure their safe use in clinical settings.
- **Trial Design:** The selection of appropriate trial designs is essential for the validity and reliability of clinical studies. Employing well-structured

randomized controlled trials (RCTs), cohort studies, or cross-sectional studies, depending on the research objective, ensures that the study results are scientifically sound. Well-considered trial designs help minimize biases and ensure robust and reproducible outcomes.

- **Sample Size Calculation:** A critical aspect of clinical research is determining the appropriate sample size to ensure that the study has enough power to detect significant effects. Adequate sample sizes are determined based on the expected effect size, variability, and significance level. Statistical methods like power analysis are applied to ensure that the study is neither underpowered (risking inconclusive results) nor overpowered (wasting resources).
- **Statistical Analysis:** Using the correct statistical methods is vital for the accurate interpretation of data in clinical trials. This includes choosing the right statistical tests (e.g., t-tests, chi-square tests, ANOVA) based on the study design and data characteristics. Advanced techniques, such as regression models and multivariate analysis, may be used to account for confounding variables and to explore complex relationships within the data.
- **Industry Participation:** Encouraging the active involvement of the AYUSH (Ayurveda, Yoga, Unani, Siddha, and Homeopathy) industry in clinical research is essential for advancing traditional medicine. Collaboration between academic researchers and industry players ensures that traditional medicine is scientifically validated and integrated into modern healthcare practices. Industry support also facilitates the availability of funding, resources, and expertise necessary to conduct high-quality studies.

RECOMMENDATION FOR VALIDATION

- **Reverse Pharmacology Model:** The Reverse Pharmacology Model, which involves starting with traditional knowledge and validating the therapeutic potential through scientific studies, offers a cost-effective and time-efficient approach to drug discovery. By focusing on known therapeutic uses of traditional medicines, this model streamlines the process of clinical validation and reduces the trial and error typically involved in drug development.
- **Minimum Standards for Scientific Validation:** The establishment of Minimum Standards (MS) for the scientific validation of traditional interventions (TIs) is essential for ensuring quality and consistency across studies. These standards would guide the design and execution of research, ensuring that studies are rigorous and results are reproducible. Clear guidelines on safety, efficacy, and quality control help to standardize the validation process and improve the credibility of findings.
- **Regulatory Mechanism for Approval:** A formalized regulatory mechanism is necessary to ensure the safety and efficacy of validated traditional

interventions. This would involve the development of a streamlined process for the approval, registration, and monitoring of these interventions, ensuring that they meet established scientific and safety standards. Such a mechanism would increase the acceptance of traditional medicines in mainstream healthcare systems and promote their widespread use.

CONCLUSION

A structured validation pathway involves precise identification of therapeutic agents, preclinical and clinical studies, and regulatory approvals. Ultimately, this validation pathway has the potential to bridge the divide between tradition and science, providing patients with safe, effective, and culturally sensitive treatment options while enriching the broader medical landscape.

REFERENCES

1. Sakagami H, editor. *Alternative Medicine*. BoD–Books on Demand, 2012 Dec 18.
2. Patwardhan B, Warude D, Pushpangadan P, Bhatt N. Ayurveda and traditional Chinese medicine: a comparative overview. *Evidence-Based Complementary and Alternative Medicine*, 2005 Dec 1; 2(4): 465-473.
3. Pal SK. Complementary and alternative medicine: an overview. *Current Science*, 2002 Mar 10; 518-524.
4. The impact of alternative medicine in the 21st century. Available from: <https://sourceessay.com/the-impactof-alternative-medicine-in-the-21stcentury/> [Accessed: 2024 November 24]
5. Cyranoski D. China is promoting coronavirus treatments based on unproven traditional medicines. *Nature*, 2020. doi: <https://doi.org/10.1038/d41586-020-01284-x>
6. Saylilg O. Ethical evaluation of clinical research on complementary and alternative medicine. *Evidence-based Medicine*, 2020 June 30. IntechOpen
7. *Alternative Medicine. Disease Prevention and Healthy Lifestyles*. <https://courses.lumenlearning.com/diseaseprevention/chapter/alternative-medical-practices/>
8. Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? *JAMA*. 2000; 283(20): 2701-2711.
9. Sung NS, Crowley WF Jr, Genel M, et al. Central challenges facing the national clinical research enterprise. *JAMA*, 2003; 289(10): 1278-1287.
10. Moher D, Sampson M, Campbell K, Beckner W, Lepage L, Gaboury I, et al. Assessing the quality of reports of randomized trials in pediatric and complementary and alternative medicine. *BMC Pediatr*, 2002; 2: 1-6.3.
11. Klassen TP, Pham B, Lawson ML, Moher D. For randomized, controlled trials, the quality of reports of complementary and alternative medicine was as good as reports of conventional medicine. *J Clin Epidemiol*, 2005; 58: 763-8.

12. Parveen I, Gafner S, Techen N, Murch S J & Khan I A, DNA barcoding for the identification of botanicals in herbal medicine and dietary supplements: Strengths and limitations, *Planta Med*, 2016; 82(14): 1225-1235.
13. Gautama P A, RCTs and other clinical trial designs in Ayurveda: A review of challenges and opportunities, *J Ayurveda Integr Med*, 2021; 12(3): 556-561.
14. Schmidt S A J, Lo S & Hollestein L M, Research techniques made simple : Sample size estimation and power calculation, *J Invest Dermatol*, 2019; 138(8): 1678-1682.
15. Kang H, Sample size determination and power analysis using the G * Power software, *J Educ Eval Health Prof*, 2021; 18(17): 1-12.
16. Wassertheil-smoller S & Kim M Y, Statistical analysis of clinical trials, *YSNUC*, 2010; 40(5): 357-363.
17. Willcox M L, Graz B, Falquet J, Diakite C, Giani S, et al., A reverse pharmacology approach for developing an anti-malarial phytomedicine, *Malar J*, 2011; 10(Suppl. 1): 1-10.
18. Surh Y-J J, Reverse pharmacology applicable for botanical drug development-inspiration from the legacy of traditional wisdom, *J Tradit Complement Med*, 2011; 1(1): 5-7.
19. Bhatt A, Phytopharmaceuticals: A new drug class regulated in India, *Perspect Clin Res*, 2016; 7(2): 59.
20. WHO Global Report on Traditional and Complementary Medicine, (World Health Organization, Geneva), 2019.
21. Ministry of Health and Family Welfare, The Drugs and Cosmetics Act and Rules, *The Gazette of India*, 1940; 1-635.
22. Good Clinical Practice Guidelines for Clinical Trials in Ayurveda Siddha and Unani Medicine, (Department of AYUSH, Ministry of Health & Family Welfare, Government of India, New Delhi), 2013.
23. Anonymous, Guidelines for the Regulation of Herbal Medicines in the South-East Asia Region, (World Health Organization, New Delhi), 2003.
24. Cuschieri S, The CONSORT statement, *Saudi J Anaesth*, 2019; 13(5): S27-S30.
25. Chan A, Tetzlaff J M & Altman D G, SPIRIT 2013 Statement : Defining standard protocol items for clinical trials, *Ann Intern Med*, 2016; 158(3): 200-207.
26. Narayana D B A & Durg S, Ayurveda: (W) here is the evidence, *J Ayurveda Integr Med*, 2021; 12(2): 408-411.
27. Luo J, Primary question and hypothesis testing in randomized controlled clinical trials, *Shanghai Arch Psychiatry*, 2016; 28(3): 177-180.
28. Torre K & Shahriari M, Clinical trials in dermatology, *Int J Women's Dermatol*, 2017; 3(3): 180-183.